$ALT News

Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026

Altimmune Details Pemvidutide’s Path Toward a Liver-Disease Franchise

Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $17

Altimmune’s (ALT) Three Liver Trials Move Forward At Once

Altimmune to Participate in the Wells Fargo 21st Annual Healthcare Conference

Altimmune's Phase III MASH Study Puts 2029 Data in Investor Focus

ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in Focus

Altimmune: Pemvidutide Performs, But A Long Wait Ahead

Altimmune Inc (ALT) (Q2 2026) Earnings Call Highlights: Advancing MASH and AUD Pipelines with ...

Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript

Altimmune Q2 Earnings Call Highlights

Altimmune, Inc. Q2 2026 Earnings Call Summary

Altimmune Announces Second Quarter 2026 Financial Results and Business Update

Altimmune Q2 EPS $(0.12) Beats $(0.15) Estimate

Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH

ALT Stock Reverses Early Gains On Positive Alcohol Use Trial — But Wall Street, Retail Investors Dismiss Selloff

Altimmune’s Pemvidutide Meets Phase II Endpoint in Alcohol Use Disorder Trial

Altimmune’s Investigational Therapy For Alcohol Use Disorder Meets Primary Endpoint – ALT Stock Jumps 10%

Altimmune Shares Jump After Positive Phase 2 Alcohol Use Disorder Trial Results